Summary
Elevated blood pressure is a major contributor to cardiovascular disease in general and to coronary heart disease in particular, now its most common sequela. The risk is proportional to the degree of blood pressure elevation, at all ages and in either sex, whether the increased pressure is labile or fixed, diastolic or systolic in character.
The effect of blood pressure on cardiovascular disease incidence is independent of the influence of other predisposing co-factors, but the hazard is greatly influenced by them. Elevated pressures are often accompanied by hyperlipidaemia, hyperuricaemia, overweight, hyperglycaemia, elevated fibrinogen values and ECG abnormalities. The risk associated with any degree of elevation of pressure varies greatly, depending on the number and level of these often associated risk factors, and on whether or not there is the indication of target organ involvement. The excess cardiovascular risk in hypertensive persons tends to be concentrated in those with an increased LDL/HDL cholesterol ratio, impaired glucose tolerance, cigarette smokers and those with accompanying ECG abnormalities.
Hypertension is best conceptualised as a component of a multivariate cardiovascular risk profile which provides a sound basis for determining urgency for drug treatment. Optimal preventive management of hypertension requires multifactorial correction of all disordered components of the cardiovascular risk profile before occurrence of target organ involvement.
Similar content being viewed by others
References
Dustan HP. Role of hypertension and its control-experimental aspects. Progress in Biochemical Pharmacology 19: 177–191, 1983
Gordon T, Kannel WB, Castelli WP, et al. Lipoproteins, cardiovascular disease and death. The Framingham Study. Archives of Internal Medicine 141: 1128–1131, 1981
Kannel WB, Sorlie P. Hypertension in Framingham. In Paul (Ed.) Epidemiology and control of hypertension, pp. 553–592. Symposia Specialists, Miami, 1975
Kannel WB, Castelli WP, Gordon T. Cholesterol in the prediction of atherosclerotic disease. New perspectives based on the Framingham Study. Annals of Internal Medicine 90: 85–91, 1979
Kannel WB, Sorlie P, Gordon T. Labile hypertension: a faulty concept? The Framingham Study. Circulation 61: 1183–1187, 1980a
Kannel WB, Dawber TR, McGee DL. Perspectives of systolic hypertension: the Framingham Study. Circulation 61: 1179–1182, 1980b
Kannel WB, Wolf PA, McGee DL, et al. Systolic blood pressure, arterial rigidity and risk of stroke. The Framingham Study. Journal of the American Medical Association 245: 1225–1228, 1981
Kannel WB, Wolf PA, Verter J. Manifestations of coronary disease predisposing to stroke. Journal of the American Medical Association 250: 2942–2946, 1983
Kannel WB, Abbott RD. Incidence and prognosis of unrecognized myocardial infarction. New England Journal of Medicine 311: 1144–1147, 1984
Smith WM. Epidemiology of hypertension. Medical Clinics of North America 61: 467–486, 1977
Stamler J. Epidemiology and treatment of hypertension. In Carlson and Cunningham (Eds) Future directions in health care: a new public policy. Ballinger, Cambridge, Mass, 1978
Tobian LJ. Interrelationships of sodium volume, CNS and hypertension. Progress in Biochemical Pharmacology 19: 208–229, 1983
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kannel, W.B. Hypertension. Drugs 31 (Suppl 1), 1–11 (1986). https://doi.org/10.2165/00003495-198600311-00004
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003495-198600311-00004